BCAB News and Press, BioAtla Inc.

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.1% to $1.85 on volume of 586,924,470 shares ProShares UltraShort Silver -2x Shares (ZSL) rose 8.5% to $2.56 on volume of 456,074,943 shares iShares Silver Trust (SLV) fell 4.0% t...

A look at the top 10 most actives in the United States China SXT Pharmaceuticals Inc. (SXTC) rose 33.9% to $0.0415 on volume of 661,694,529 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.0% to $1.8515 on volume of 515,170,719 shares ProShares UltraShort Silver -2x Shares (...

2026-01-16 14:42:41 ET More on healthcare stocks XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins? IYH: Elevated Valuations And Slowing Growth Signal Subpar 2026 Returns Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Cat...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026. BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the S...

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year end ...

2025-11-13 18:52:16 ET More on BioAtla BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioAtla Historical earnings data for BioAtla Financial information for BioAtla Read the full article on Seeking Alpha...

2025-11-13 18:51:33 ET BioAtla, Inc. (BCAB) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay Short - Co-Founder, CEO & Chairman Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Richard Waldron - Seni...

2025-11-13 16:11:42 ET More on BioAtla Seeking Alpha’s Quant Rating on BioAtla Historical earnings data for BioAtla Financial information for BioAtla Read the full article on Seeking Alpha For further details see: BioAtla GAAP EPS of -$0.08...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval Company is in advanced stages to finalize a strategic transaction with a potential partn...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...